Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 902 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Choice given Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Treatment of Intrapartum Depression Using Non-invasive Photobiomodulation

NCT04404231
View directory record Official record
Conditions
Depression, Pregnancy Related, Intrapartum Depression
Interventions
Delivery of infrared light to the head, No Infrared treatment
Radiation · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 22, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

The Medically Tailored Groceries and Mental Health Study

NCT07779707
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Food Insecurity
Interventions
Medically Tailored, Home-delivered Groceries, Active Comparison Group: Monthly Grocery Gift Card
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

NCT01576692
View directory record Official record
Conditions
Neuroblastoma
Interventions
Humanized anti-GD2 antibody, Chemotherapy, Cytokines, Natural killer cells, CliniMACS
Biological · Drug · Other + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01460134
View directory record Official record
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

NCT00217412
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, isotretinoin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy

NCT03469999
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Dysport Injectable Product
Drug
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 22, 2026, 6:12 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 105 Years
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01835548
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
NT0102, Placebo
Drug
Lead sponsor
Neos Therapeutics, Inc
Industry
Eligibility
6 Years to 12 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Not applicable Interventional

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

NCT00521196
View directory record Official record
Conditions
Migraine
Interventions
DC Stimulator (Transcranial Direct Current Stimulator)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 22, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

NCT06171269
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, MRI, Androgen Deprivation Therapy
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer

NCT01670461
View directory record Official record
Conditions
Cancer
Interventions
FACE, Standard of Care (SOC) Control
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
14 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 22, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 6:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

NCT05896839
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy, Magnetic Resonance Imaging, Nivolumab, Prednisone, Sirolimus
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Not applicable Interventional

Decisional Quality for Patients With Coronary Artery Disease

NCT02145481
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Decision Aid, CAD Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Not applicable Interventional

A Novel Fully Integrated Mobile Management Solution Using Cell Phone Technology for Heart Failure

NCT02935439
View directory record Official record
Conditions
Heart Failure
Interventions
Cell Phone
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Swallowing Pressure Profiles in Healthy Adults

NCT03986554
View directory record Official record
Conditions
Healthy
Interventions
Videofluoroscopic swallow study, pharyngeal High Resolution Manometry
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 22, 2026, 6:12 PM EDT
Terminated Phase 3 Interventional Results available

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

NCT02718417
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
146
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 22, 2026, 6:12 PM EDT
Withdrawn Not applicable Interventional

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

NCT00459225
View directory record Official record
Conditions
Anemia
Interventions
Iron (ferrous sulfate)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 2 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 22, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reactive Balance Training for Fall Prevention

NCT04205279
View directory record Official record
Conditions
Healthy Young, Healthy Aging, Stroke
Interventions
Experimental: Treadmill training, Experimental: Overground training, Experimental: Surefooted training
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 6:12 PM EDT
Completed No phase listed Observational

Diabetes Attitudes Wishes and Needs

NCT01507116
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Relatives to/Carers of Patients, Healthcare Professionals
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
8,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 22, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

Photobiomodulation for Management of Temporomandibular Disorder Pain

NCT05916235
View directory record Official record
Conditions
Pain Related to TMD
Interventions
THOR® laser system
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 22, 2026, 6:12 PM EDT
Active, not recruiting Phase 2 Interventional

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685
View directory record Official record
Conditions
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 22, 2026, 6:12 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Nurse Family Partnership for Women With Previous Live Births

NCT05887115
View directory record Official record
Conditions
Pregnancy, High Risk, Child Development, Post Partum Depression
Interventions
Nurse Family Partnership
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 46 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 22, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease

NCT00976352
View directory record Official record
Conditions
Pompe Disease
Interventions
rAAV1-CMV-GAA (study agent) Administration, RMST
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 22, 2026, 6:12 PM EDT